Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NEU 2000

Drug Profile

NEU 2000

Alternative Names: Neu2000; Neu2000KL

Latest Information Update: 05 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amkor Pharma
  • Developer AmKor Pharma; GNT Pharma
  • Class Benzoic acids; Neuroprotectants; Small molecules; Vascular disorder therapies
  • Mechanism of Action Antioxidants; NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stroke
  • Preclinical Burns
  • No development reported Myocardial infarction; Spinal cord injuries

Most Recent Events

  • 05 Sep 2018 GNT Pharma plans a phase II trial for Heart Arrest in Korea (IV) (NCT03651557)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Stroke in USA (IV, Infusion)
  • 16 May 2016 The Korea Ministry of Food and Drug Safety approves IND application for Neu 2000 in Stroke
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top